AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02858518 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
Study NCT01642030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydromorphone
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study NCT00812305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402 300mg in healthy patients
Description: SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
Study NCT00812305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402 300mg in hepatically impaired patients
Description: SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
Study NCT01642030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study NCT03278808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine-Azithromycin (CQ/AZ)
Description: Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
Study NCT03278808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine (CQ)
Description: Chloroquine (CQ); 300 mg of CQ only given orally
Study NCT03278808 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: atovaquone-proguanil (Malarone®)
Description: All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
Study NCT04297423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plenvu
Description: randomization 1:1
Study NCT04297423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plenvu
Description: randomization 1:1
Study NCT00425906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Study NCT00425906 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00425906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality of life
Study NCT00425906 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quality of life
Study NCT01234428 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic surgery
Description: Gastric banding
Study NCT02325258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone call
Description: Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
Study NCT00608387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic disease management Web-based software
Description: Participants will have access to remotely based medical providers through the use of the Web-based software.
Study NCT03204045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fentanyl
Description: 2 mL mixture of fentanyl with isotonic saline
Study NCT03204045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: 2 mL mixture of fentanyl with isotonic saline
Study NCT03204045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 2 mL mixture of oxycodone with isotonic saline
Study NCT03204045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 2 mL mixture of oxycodone with isotonic saline
Study NCT03204045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: isotonic saline 2 mL
Study NCT02030847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10\^8 transduced CAR T cells
Study NCT02030847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: As of June 2014, dose was reduced to a single dose of 1-5x10\^7 CART-19 cells.
Study NCT02030847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: In the protocol amendment in November 2014, the dose remained 1-5 x 10\^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
Study NCT02030847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: In the protocol amendment in May 2015, the dose was changed to 1-5 x 10\^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10\^7), 30% on Day 2 (3x10\^7-1.5x10\^8), 60% on Day 3 (6x10\^7-3x10\^8).
Study NCT02444884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237
Study NCT03948815 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: interventional birthing room
Description: The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
Study NCT03948815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interventional birthing room
Description: The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
Study NCT04501354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell
Description: Mesenchymal Stem Cell + NaCl 0,9% 2ml
Study NCT03185910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCP education
Description: MBCP education involves mindfulness breathing and other skills with mindfulness meditations.
Study NCT03185910 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hospital-based antenatal education
Description: Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
Study NCT00003588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5CMV-p53 gene
Study NCT00003588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Study NCT05591456 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjuvant radiotherapy
Description: Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
Study NCT01234428 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: gastric banding
Description: laparoscopic gastric banding
Study NCT03185299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
Study NCT03185299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard preparation instructions
Description: The control arm will receive written instruction on preparing for a colonoscopy per standard of care
Study NCT00904189 — intervention group
Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Standard of care given for treatment of cancer
Description: Subjects receiving a known dose of radiation during Total Body Irradiation.
Study NCT00348569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 64 Channel VCT
Study NCT04309955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pigtail catheter
Description: After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
Study NCT02475967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.The content of platform will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists). Patients will also contribute to platform content.
Study NCT02475967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group patients receive conventional cardiac care alone.
Study NCT02949778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL-block
Description: Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
Study NCT02949778 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: QL-block
Description: Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
Study NCT02949778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 3.75mg/ml administered in QL-block as active treatment
Study NCT02949778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium chloride 9mg/mL administered in QL-Block as placebo
Study NCT03550794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine Hydrochloride
Description: Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
Study NCT03550794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50ml of 0.9% NACL will serve as the placebo
Study NCT00751972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartWare® VAS
Description: The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
Study NCT00918697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical debridement
Description: For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
Study NCT00918697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol-assisted debridement
Description: For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
Study NCT04207554 — intervention group
Intervention type: DEVICE
Intervention: Test Device-Strip Format
Description: Sponsor's investigational device
Study NCT04207554 — intervention group
Intervention type: DEVICE
Intervention: Test Device-Cassette Format
Description: Sponsor's investigational device
Study NCT04207554 — intervention group
Intervention type: DEVICE
Intervention: Predicate Device
Description: Commercially available device
Study NCT04185831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PD-L1 inhibitor
Study NCT04185831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: MTOR inhibitor
Study NCT04185831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: MEK inhibitor
Study NCT04185831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: PARP inhibitor
Study NCT02715466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced gelatine solution
Description: Gelaspan combined with Sterofundin ISO
Study NCT02715466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced electrolyte solution
Description: Sterofundin ISO
Study NCT02715466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced electrolyte solution
Description: Sterofundin ISO
Study NCT01856374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)
Description: Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
Study NCT01856374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)
Description: Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
Study NCT01856374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin 20mg
Description: 2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
Study NCT01856374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: 2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
Study NCT02162901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice-Class with IVR Calls
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
Study NCT02162901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Random-Class with IVR calls
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
Study NCT02162901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Random-Class only
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
Study NCT02162901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice-DVD with IVR calls
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
Study NCT02162901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Random-DVD with IVR calls
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
Study NCT02970175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin administration
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
Study NCT02970175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopy under local anesthesia
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
Study NCT02970175 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bronchoscopy under local anesthesia
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
Study NCT02970175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy sampling
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
Study NCT02970175 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy sampling
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
Study NCT02655913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive care
Description: Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
Study NCT02258477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 1
Description: 100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
Study NCT02258477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 2
Description: Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
Study NCT02258477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 3
Description: 50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
Study NCT02258477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 4
Description: 10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
Study NCT00355082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine, 300 mg/day
Description: 300 mg/day
Study NCT00355082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine, 250 mg/day
Description: 250 mg/day
Study NCT03934502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
Study NCT02655913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care
Description: Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
Study NCT00965523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate 1.4 mg/m\^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
Study NCT02165150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair-bound Senior Elastic Band exercise program
Description: three times per week, 40 minutes per practice
Study NCT04504045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg tablet